DiaMedica Therapeutics Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging -3.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.19 | $-0.19 | +0.0% | Beat | |
| Q1 FY26 | $-0.17 | $-0.19 | -11.8% | Miss | |
| Q4 FY25 | $-0.17 | $-0.17 | +0.0% | Beat |
Back to DMAC overview · DMAC holders · DMAC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.